DE BERNARDI ELISABETTA
- U48, Floor: 1I, Room: 115
- U28, Floor: 0, Room: T021
Biography
2002 Degree in Biomedical Engineering, Politecnico di Milano
2007 PhD in Bioengineering, Politecnico di Milano
2007-2011 Research fellow, Politecnico di Milano
since 11/2011 Assistant Professor SSD ING-INF/06, Università di Milano Bicocca
Research
Research topics: biomedical image reconstruction, segmentation and quantification; radiomics and deep radiomics.
Publications
Cerina, V., Rui, C., DE BERNARDI, E., Moresco, R., Giussani, C., Basso, G., et al. (2024). Preliminary assessment of semiautomated segmentation tool for GBM neurosurgery: a BraTS-Toolkit approach. Intervento presentato a: 19th European Molecular Imaging Meeting - EMIM (European Society of Molecular Imaging - ESMI) - 12-15 March, Porto, Portugal. Detail
Maino, C., Vernuccio, F., Cannella, R., Franco, P., Giannini, V., Dezio, M., et al. (2024). Radiomics and liver: Where we are and where we are headed?. EUROPEAN JOURNAL OF RADIOLOGY, 171(February 2024) [10.1016/j.ejrad.2024.111297]. Detail
Cerina, V., Crivellaro, C., Morzenti, S., Pozzi, F., Bigiogera, V., Jonghi-Lavarini, L., et al. (2024). A ROI-based quantitative pipeline for 18F-FDG PET metabolism and pCASL perfusion joint analysis: Validation of the 18F-FDG PET line. HELIYON, 10(1) [10.1016/j.heliyon.2023.e23340]. Detail
Meazza Prina, M., Gotuzzo, I., Cazzaniga, M., De Bernardi, E., Cafaro, P., Capici, S., et al. (2023). Baseline 18FDG-PET Metabolic Tumour Volume (MTV) as a Potential Predictive Factor of Response to Metronomic Chemotherapy (mCHT) in HR+/HER2- Metastatic Breast Cancer (MBC) Patients (pts). Preliminary Results of the Metro-pet Study. Intervento presentato a: SABCS - San Antonio Breast Cancer Symposium - DEC 06-10, 2022, San Antonio, Texas, USA [10.1158/1538-7445.SABCS22-P6-01-42]. Detail
Bonaffini, P., De Bernardi, E., Corsi, A., Franco, P., Nicoletta, D., Muglia, R., et al. (2023). Towards the Definition of Radiomic Features and Clinical Indices to Enhance the Diagnosis of Clinically Significant Cancers in PI-RADS 4 and 5 Lesions. CANCERS, 15(20) [10.3390/cancers15204963]. Detail